Xiaodong Wang Net Worth

Xiaodong Wang biography

Dr. Xiaodong Wang Ph.D. serves as Co-Founder, Non-Executive Director of the Company. He is our Co-Founder and has served as a member of our Board of Directors since February 2016. He has also served as the Chairman of our Scientific Advisory Board since 2011. Dr. Wang has served as the founding Director of the National Institute of Biological Sciences in Beijing since 2003 and became its Director and Investigator in 2010. Previously, he was a Howard Hughes Medical Institute Investigator from 1997 to 2010 and held the position of the George L. MacGregor Distinguished Chair Professor in Biomedical Sciences at the University of Texas Southwestern Medical Center in Dallas, Texas from 2001 to 2010. In 2004, Dr. Wang founded Joyant Pharmaceuticals, Inc., a venture capital-backed biotechnology company focused on the development of small molecule therapeutics for cancer. Dr. Wang received his B.S. in Biology from Beijing Normal University in July 1984 and his Ph.D. in Biochemistry from the University of Texas Southwestern Medical Center in May 1991. Dr. Wang has been a member of the National Academy of Science, USA since 2004 and a foreign associate of the Chinese Academy of Sciences since 2013. Wang’s extensive experience in cancer drug research, combined with his experience in the biotech industry, qualify him to serve as a member of our Board of Directors.

What is the salary of Xiaodong Wang?

As the Co-Founder and Non-Executive Director of BeiGene Ltd, the total compensation of Xiaodong Wang at BeiGene Ltd is $6,627,000. There are 1 executives at BeiGene Ltd getting paid more, with John Oyler having the highest compensation of $13,899,000.

How old is Xiaodong Wang?

Xiaodong Wang is 57, he's been the Co-Founder and Non-Executive Director of BeiGene Ltd since 2016. There are 8 older and 12 younger executives at BeiGene Ltd. The oldest executive at BeiGene Ltd is Donald Glazer, 75, who is the Non-Executive Independent Director.

Insiders trading at BeiGene Ltd

Over the last 9 years, insiders at BeiGene Ltd have traded over $1,899,158,980 worth of BeiGene Ltd stock and bought 23,241,738 units worth $1,040,248,444 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Investment Management, Ltd...., and Bros. Advisors Lp Baker Bro.... On average, BeiGene Ltd executives and independent directors trade stock every 13 days with the average trade being worth of $33,382,815. The most recent stock trade was executed by Xiaobin Wu on 3 September 2024, trading 5,556 units of BGNE stock currently worth $1,053,695.

What does BeiGene Ltd do?

BeiGene is a biotechnology company that specializes in the development of drugs for cancer treatment. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib.

BeiGene Ltd executives and stock owners

BeiGene Ltd executives and other stock owners filed with the SEC include:

• John Oyler,
  Co-Founder, Executive Chairman of the Board, Chief Executive Officer
• Xiaodong Wang,
  Co-Founder, Non-Executive Director
• Dr. Xiaodong Wang Ph.D.,
  Co-Founder, Chairman of the Scientific Advisory Board & Non-Exec. Director
• John V. Oyler,
  Co-Founder, Exec. Chairman & CEO
• Dr. Xiaobin Wu Ph.D.,
  Pres, COO & GM of China
• Wang Lai,
  Global Head of R&D
• Dr. Edna Huang M.D.,
  Chief Medical Officer of Hematology
• Dr. Jane Edna Huang M.D.,
  Chief Medical Officer of Hematology
• Dr. Heng Liang,
  CFO & Chief Strategy Officer
• Thomas Malley,
  Non-Executive Independent Director
• Qingqing YI,
  Non-Executive Independent Director
• Timothy Chen,
  Non-Executive Independent Director
• Jing-Shyh Su,
  Non-Executive Independent Director
• Donald Glazer,
  Non-Executive Independent Director
• Ranjeev Krishana,
  Non-Executive Independent Director
• Michael Goller,
  Non-Executive Independent Director
• Corazon Sanders,
  Non-Executive Independent Director
• Anthony Hooper,
  Non-Executive Director
• Hing Ling Chau,
  Company Secretary
• Jane Huang,
  Chief Medical Officer, Hematology
• Xiaobin Wu,
  General Manager - China, President
• Kevin C. Mannix,
  Sr. VP of Investor Relations.
• Mi Zhou,
  Sr. Director of Investor Relations
• Julia Wang,
  CFO & Principal Accounting Officer
• Diana Lee Francis,
  VP and Global Head of Quality & Regulatory Compliance
• Scott Samuels,
  Sr. VP & Gen. Counsel
• Craig West CFA,
  Sr. Director of Investor Relations
• Michael Garvey,
  Global Head of Technical Operations
• Daniel Maller,
  VP of Fin. & Accounting
• Jianxin Yang,
  Sr. VP, Head of Clinical Dev.
• Amy C. Peterson,
  CMO, Immuno-oncology
• Ji Li,
  EVP and Gl. Head of Bus. Dev.
• Investment Management, Ltd....,
  10% owner
• Rui Rong Yuan,
  Chief Medical Officer
• Ke Tang,
  Director
• Bros. Advisors Lp Baker Bro...,
  
• Biotech Investment Ltd Cpe ...,
  
• Wendy Xiaojun Yan,
  Sr. VP, Head of Reg. Affairs
• & Co., Inc.Merck Sharp & Do...,
  
• Chan Henry Lee,
  SVP, General Counsel
• Bros. Advisors Lp14159, L.P...,
  
• Bros. Advisors Lp667, L.P.B...,
  
• Howard Liang,
  CFO & Chief Strategy Officer
• Inc Amgen,
  10% owner
• Lai Wang,
  Global Head of R&D
• Olivier Brandicourt,
  Director
• Julia Aijun Wang,
  Chief Financial Officer
• Margaret Dugan,
  Director
• Advisors, Ltd.Hillhouse Inv...,
  
• Bros. Advisors Lp667, L.P.B...,
  
• Titus B. Ball,
  Principal Accounting Officer
• Aaron Rosenberg,
  Chief Financial Officer